Overview

Regorafenib Combined With Irinotecan as Second-line in Patients With Metastatic Gastro-oesophageal Adenocarcinomas

Status:
Active, not recruiting

Trial end date:
2023-11-01

Target enrollment:

Participant gender:

Summary

Trial evaluating the efficacy of regorafenib combined with irinotecan compared to irinotecan alone in second-line treatment of patients with metastatic gastro-oesophageal adenocarcinomas.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

UNICANCER

Treatments:

Camptothecin
Irinotecan